Company intelligence / Profile preview

1CellBio

Watertown, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

1CellBio commercializes the inDrop™ System, a high-resolution, single-cell transcriptomics platform offering greater experimental control, rare actionable information and lower cost per result compared to existing platforms[1]. The company has expanded capabilities to include targeted cell selection and sequencing, demonstrated in peer-reviewed publications for applications such as antibody discovery and immune profiling[2]. Recent innovations include the TruDrop dual indexed library design capability, which improves costs, throughput and data quality for large-scale single-cell RNA sequencing studies[7].

Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Vanderbilt University Medical CenterRootPath GenomicsOpen Medicine InstituteHarvard University (founding)

Beyond the preview

Go deeper on 1CellBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1CellBio.

Explore the full profile